ClinicalTrials.gg
RecruitingNCT06471556CORTICONEHIUpdated Aug 27, 2025

Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study

A Phase 2 interventional study of IV Methylprednisolone pulses in Neuroendocrine Cell Hyperplasia of Infancy, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged Up to 12 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
Up to 12 Years
Sex
All
01

Study summary

Childhood interstitial lung diseases (chILD) are a heterogeneous group of rare and severe disorders with an estimated prevalence of 1/100,000. Among them, neuroendocrine cells hyperplasia of infancy (NEHI), also called persistent tachypnoea of infancy (PTI), is one of the most common aetiology (up to 16% of the cases). NEHI involves young infants (median age at onset 3 to 6 months) with tachypnoea, hypoxemia, crackles, retractions, failure to thrive and specific localizations of ground glass opacities (GGO) on chest CT-scan (paramediastinal areas and anterior lobes (right middle lobe and lingula). At diagnosis, most patients (50 to 100%) require oxygen supplementation that usually lasts for months to years, sometimes associated with nutritional support with eventual enteral nutrition. NEHI is believed to be related to an increased number of neuroendocrine cells in airway epithelial area. These cells are abundant in foetal life, when they play a role in regulating the lung development and decrease before birth.

There is no specific treatment for NEHI. The main treatment of chILD is corticosteroids. However, in NEHI, their efficacy is matter of debate. There is only a few NEHI cases series or cohorts all over the world, accounting for a maximum of 500 reported cases within only retrospective studies. Among them, United States and Argentina teams report supportive care only (oxygen therapy and nutritional support) whereas other teams, like the French ones largely uses IV corticosteroid pulses.

Unlike the majority of chILD, NEHI prognosis is usually good. However, at school-age, 26% of the patients remain symptomatic or have an abnormal lung function. Moreover, oxygen therapy significantly affects quality of life (QoL) of the children with ILD (-10.43/100 points, p=0.02) but also QoL and mood of their parents (unpublished data).

The present study hypothesis that corticosteroids are associated with a reduction of the length of oxygen support in infants with NEHI.

Read the detailed description

This study aims at assessing the beneficial effect of IV methylprednisolone pulses on oxygen therapy in infants with NEHI. It applies to all hypoxic NEHI patients aged below 12 months and followed in one of the centres of the RespiRare network. 18 patients will be recruited.

CORTICO-NEHI is designed as an early phase study following an A'Hern's Single Stage Phase II design.

All the patients are included in a single group receiving as a standard of care a maximum of 6 IV pulses of 3 days each.

12 visits will be performed as a standard of care:

  • Screening visit (M-1 at maximum) :follow-up routine visit, (usually the hospitalization for NEHI diagnosis). If the patient is eligible, parents are informed of the study and an informed note is given. Information on the study protocol is given to obtain their written consent as soon as possible, and at the latest at the inclusion.
  • Inclusion (M0) : After checking of the inclusion criteria and the absence of exclusion criteria, information and collection of parental consent. Following these investigations, the patient's first IV methylprednisolone pulse (D1) is administrated within the limit of 10 days.
  • Treatment visits (M0 - M5): During a hospitalization, 6 pulses are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure / 30min. If oxygen can be stopped (2 oxymetries with a 1-week interval +/- 10 days): The endpoint is reached and the methylprednisolone pulses are definitively stopped.
  • Follow-up visits (M6, M9, M12, M15 and M18)

For the research needs,

  • CT scan and Echocardiography will be done at inclusion if not performed in the past 3 months
  • QoL questionnaires will be performed at inclusion, M6, M12 and M18
  • Dipstick for sugar will be performed at M6, M9, M12, M15, M18 (in addition to M0 - M5 according to the standard of care)
02

Conditions studied

  • Neuroendocrine Cell Hyperplasia of Infancy

Browse trials for

Keywords

  • neuroendocrine cells hyperplasia of infancy (NEHI)
  • Persistent tachypnoea of infancy (PTI)
  • Childhood interstitial lung diseases (chILD)
  • IV Corticosteroids pulses
  • Methylprednisolone
  • Oxygen therapy
03

In context

Hyperplasia

76 studies on the registry are indexed under Hyperplasia; 9 are open to participants now.

This study's planned enrollment of 18 is below the median of 60 across 51 interventional studies indexed under Hyperplasia.

Browse Hyperplasia studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infant aged under 12 months
  • NEHI diagnosis based on:

    • The recently validated clinical Liptzin score ≥7/10 associated with a suggestive thoracic CT pattern with ground glass opacities confined to middle lobe, lingula, and paramediastinal lung areas OR
    • a clinical and thoracic CT suspicion and a lung showing an increased number of neuroendocrine cells in the epithelial airways area (at least one bronchiole with at least 10% of neuroendocrine cells)
  • Oxygen requirement (awake and/or asleep) based on the usual pediatric recommendations (see section 4.1.1)
  • Followed in one of the RespiRare participating centers
  • Written of the holder(s) of its legal representative at the inclusion

Exclusion criteria

Exclusion Criteria:

  • Other cause of chILD assessed by lab biology tests, genetic analysis for surfactant genes (if available), bronchoalveolar lavage, and/or lung .
  • Patient treated with IV methylprednisolone pulses before (any time)
  • Diabetes
  • Uncontrolled arterial hypertension
  • Absence of Health care insurance
  • Ongoing infection
  • Immunization with a within the past two weeks
  • Long term treatment with Azithromycin and/or Hydroxychloroquine
  • Patients already included in an interventional study (RIPH1, clinical investigation or clinical trial)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    IV Methylprednisolone pulses

    Drug: IV Methylprednisolone pulses

Interventions

  • DrugIV Methylprednisolone pulses

    Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /

06

What researchers measure

Primary outcomes

  1. Number of children still requiring oxygen therapy

    To evaluate the efficacy on oxygen therapy need of a 6 months methylprednisolone pulses in NEHI patients at M18.

    Time frame: Month 18

Secondary outcomes

  1. Time to achieve the oxygen therapy weaning

    Duration between randomization and the absence of oxygen therapy requirement at M18

    Time frame: Month 18

  2. The number of patients requiring continuous oxygen therapy (meaning sleep and awake oxygen therapy by opposition to sleep oxygen only) over time

    Number of children still requiring oxygen therapy/ Number of children requiring only sleep oxygen

    Time frame: Month 18

  3. The number of patients requiring only sleep oxygen over time

    Number of children requiring only sleep oxygen

    Time frame: Month 18

  4. The number of patients with a normal respiratory rate

    Number of children with a normal respiratory rate at rest

    Time frame: Month 18

  5. ChILD healing (reduction of severity) over time

    Difference of Fan's severity score assessing the severity of children with ILD (respiratory symptoms, SpO2\<90% at sleep or exertion, SpO2\<90% at rest and pulmonary hypertension)

    Time frame: Between Month 0 and Month 18

  6. Parents QoL

    Family impact PedsQL score and a parents QoL score (submitted for publication)

    Time frame: Month 0 and Month 18

  7. Patient's QoL

    Patients impact PedsQL and the chILD QoL scores; the chILDPQoL score.

    Time frame: Month 0 and Month 18

  8. Impact of NEHI on feeding and growth status

    Number of patients requiring at least one enteral nutrition episode (based on the physician appreciation in case of abnormal weight curve)

    Time frame: Between Month 0 and Month 18

  9. Safety of methylprednisolone pulses

    Number of unexpected hospitalizations for a respiratory exacerbation

    Time frame: Between Month 0 and Month 18

  10. Number of antibiotic courses for an infectious lung exacerbation

    Safety of methylprednisolone pulses

    Time frame: Between Month 0 and Month 18

  11. Safety of methylprednisolone pulses

    * the number of patients with at least once systolic or diastolic arterial blood pressure (AP) over 2SD for the age at the days of methylprednisolone pulses * the number of patients with at least one elevated fasting glycaemia before the first day of methylprednisolone pulses.

    Time frame: At Month 6

  12. Safety of methylprednisolone pulses

    \- the number of patients with at least one elevated fasting glycaemia before the first day of methylprednisolone pulses.

    Time frame: At Month 6

  13. To compare the family impact PedsQL questionnaire to the newly described chILD-PQoL questionnaire

    Correlation between family impact PedsQL questionnaire and the newly described chILD-PQoL questionnaire

    Time frame: Month 0, Month 6, Month 12, Month 18

  14. To study thoracic CT-scan evolution

    Number of patients with an extension, a stability, a decrease or an absence of the GGO lesions on the CT-scan

    Time frame: at Month 6 and Month 18

07

Study locations

1 of 1 sites recruiting
  • Pediatric Pulmonology Department and Reference centre for rare lung diseases
    Paris, 75012, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Feb 2029, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 24, 2024
StartActual
Jun 30, 2025
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06471556
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jun 30, 2025
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Aug 27, 2025

Study contacts

Nadia NATHAN
Contact
nadia.nathan@aphp.fr
00 33 1 44 73 66 18
Ralph EPAUD
Contact
ralph.epaud@chicreteil.fr
00 33 1 45 17 53 98
Nadia NATHAN
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion